Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways

Cellular Physiology and Biochemistry

Volumn 26, Issue 4-5, 2010, Pages 609-618

  Lu, Ze J ^a   Zhou, Yan ^a   Song, Qi ^a   Qin, Zhao ^b   Zhang, Hong ^b   Zhou, Yong J ^a   Gou, Lan T ^a   Yang, Jin L ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN NORMAL UNIVERSITY   (China)

Author keywords

AKT; Antitumor Agent; ERK; Lung Cancer; Periplocin

Indexed keywords

ANTINEOPLASTIC AGENT; CARDENOLIDE DERIVATIVE; CASPASE 3; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE; PERIPLOCIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 78149461619     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322328     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Rajeswaran A, Trojan A, Burnand B, Giannelli M: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemo-therapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008;59:1-11.
3. Efferth T, Li PC, Konkimalla VS, Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:353-361.
4. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R: Cardiotonic steroids on the road to anti-cancer therapy.Biochim Biophys Acta 2007;1776:32-57.
5. Winnicka K, Bielawski K, Bielawska A, Surazyñski A: Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. Biol Pharm Bull 2008;31:1131-1140.
6. Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM: Phase 1 trial of Anvirzel in patients with refractory solid tumors.Invest New Drugs 2006;24:423-427.
7. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007;293:C509-536.
8. Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
9. Singh R, George J, Shukla Y: Role of senescence and mitotic catastrophe in cancer therapy. Cell Div 2010;5:4.
10. Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I: Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 2004;101:1908-1918.
11. Vicent S, López-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchón C: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004;90:1047-1052.
12. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059.
13. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA: Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005;65:5054-5062.
14. Bloise E, Braca A, De Tommasi N, Belisario MA: Pro-apoptotic and cytostatic activity of naturally occurring cardenolides. Cancer Chemother Pharmacol 2009;64:793-802.
15. Masamha CP, Benbrook DM: Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 2009;69:6565-6572.
16. Autret A, Martin SJ: Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell 2009;36:355-363.
17. Brenner D, Mak TW: Mitochondrial cell death effectors. Curr Opin Cell Biol 2009;21:871-877.
18. Toker A, Yoeli-Lerner M: Akt signaling and cancer: surviving but not moving on. Cancer Res 2006;66:3963-3966.
19. Anjum R, Blenis J: The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747-758.
20. Du Y Y, Liu X, Shan BE: Periplocin extracted from cortex periplocae induces apoptosis of SW480 cells through inhibiting the Wnt/beta-catenin signaling pathway. Ai Zheng 2009;28:456-460.
21. Fulda S: Apoptosis pathways and neuroblastoma therapy. Curr Pharm Des 2009;15:430-435.
22. Smith DJ, Ng H, Kluck RM, Nagley P: The mitochondrial gateway to cell death. IUBMB Life 2008;60:383-389.
23. Wang H, Haas M, Liang M, Cai T, Tian J, Li S, Xie Z: Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase. J Biol Chem 2004;279:17250-17259.
24. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006;118:209-214.
25. Newman RA, Yang P, Pawlus AD, Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008;8:36-49.